Bio-Rad Laboratories (BIO) News Today → How to Play the AI and Crypto Markets in One Swing (From Weiss Ratings) (Ad) Free BIO Stock Alerts $300.97 +6.96 (+2.37%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 8:05 AM | marketbeat.comJump Financial LLC Purchases Shares of 5,163 Bio-Rad Laboratories, Inc. (NYSE:BIO)Jump Financial LLC purchased a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,163 shares of the medical reseMay 15 at 7:24 AM | marketbeat.comBio-Rad Laboratories Q1 Earnings TranscriptMay 15 at 2:56 AM | americanbankingnews.comBio-Rad Laboratories (NYSE:BIO) Stock Rating Lowered by StockNews.comMay 14 at 12:04 AM | markets.businessinsider.comPrecision BioSciences earnings: here's what Wall Street expectsMay 12 at 11:47 PM | marketbeat.comRoubaix Capital LLC Makes New $4.05 Million Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO)Roubaix Capital LLC purchased a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 12,549 shares of the medical research comMay 11, 2024 | marketbeat.comMawer Investment Management Ltd. Cuts Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)Mawer Investment Management Ltd. reduced its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 23.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 123,878 shares of the medical researcMay 11, 2024 | americanbankingnews.comBio-Rad Laboratories (NYSE:BIO) PT Lowered to $385.00 at UBS GroupMay 10, 2024 | marketbeat.comNatixis Advisors L.P. Boosts Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)Natixis Advisors L.P. raised its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 17.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,744 shares of theMay 9, 2024 | marketbeat.comSwiss National Bank Sells 3,400 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)Swiss National Bank lowered its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 4.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 67,600 shares of the medical research company's stock after selling 3,400 shares during the periMay 8, 2024 | marketbeat.comBio-Rad Laboratories (NYSE:BIO) Releases Quarterly Earnings Results, Beats Expectations By $0.25 EPSBio-Rad Laboratories (NYSE:BIO - Get Free Report) released its earnings results on Tuesday. The medical research company reported $2.29 EPS for the quarter, beating the consensus estimate of $2.04 by $0.25. The firm had revenue of $610.82 million during the quarter, compared to analysts' expectations of $619.09 million. Bio-Rad Laboratories had a negative net margin of 23.86% and a positive return on equity of 3.90%. The business's quarterly revenue was down 9.8% compared to the same quarter last year. During the same period in the prior year, the company earned $3.34 EPS.May 8, 2024 | marketbeat.comBio-Rad Laboratories (NYSE:BIO) Price Target Cut to $385.00 by Analysts at UBS GroupUBS Group decreased their price objective on Bio-Rad Laboratories from $420.00 to $385.00 and set a "buy" rating for the company in a report on Wednesday.May 8, 2024 | finance.yahoo.comQ1 2024 Bio Rad Laboratories Inc Earnings CallMay 7, 2024 | markets.businessinsider.comBIO Stock Earnings: Bio-Rad Laboratories Beats EPS, Misses Revenue for Q1 2024May 7, 2024 | reuters.comBio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slipMay 7, 2024 | businesswire.comBio-Rad Reports First-Quarter 2024 Financial ResultsMay 7, 2024 | marketbeat.comTruist Financial Corp Cuts Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)Truist Financial Corp trimmed its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 21.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,635 shares of the medical research company's stock aftMay 5, 2024 | marketbeat.comFisher Asset Management LLC Sells 14,338 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)Fisher Asset Management LLC lowered its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 15.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 80,570 shares of the medical research company's stock after selling 14,33May 5, 2024 | americanbankingnews.comBio-Rad Laboratories (BIO) Set to Announce Quarterly Earnings on TuesdayMay 1, 2024 | finance.yahoo.comBio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare ConferenceMay 1, 2024 | businesswire.comBio-Rad's Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare ConferenceApril 30, 2024 | marketbeat.comBio-Rad Laboratories (BIO) Scheduled to Post Earnings on TuesdayBio-Rad Laboratories (NYSE:BIO) will be releasing earnings after the market closes on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=586339)April 29, 2024 | marketbeat.comAnchor Capital Advisors LLC Sells 20,844 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)Anchor Capital Advisors LLC lowered its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 21.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 76,698 shares of the mApril 28, 2024 | marketbeat.comIFM Investors Pty Ltd Makes New Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO)IFM Investors Pty Ltd bought a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 4,057 shares of the medical research company's stock, valued at approxApril 27, 2024 | marketbeat.comSector Gamma AS Makes New $7.62 Million Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO)Sector Gamma AS bought a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 23,609 shares of the medical research company's stock, valued at approximatelyApril 26, 2024 | businesswire.comBio-Rad Announces Life Science Group Management ChangesApril 23, 2024 | usatoday.comS&P 500 (SPX) today: Top movers are Bio-Rad Laboratories Inc and Agilent Technologies, Inc.April 22, 2024 | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) Shares Bought by Duality Advisers LPDuality Advisers LP grew its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 431.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,564 shares of the medical research company's stock after acquiring an additional 6,953April 20, 2024 | marketbeat.comKornitzer Capital Management Inc. KS Cuts Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)Kornitzer Capital Management Inc. KS lessened its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 9.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,647 shares ofApril 19, 2024 | nasdaq.comCommit To Purchase Bio-Rad Laboratories At $185, Earn 1.3% Annualized Using OptionsApril 18, 2024 | businesswire.comBio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024April 17, 2024 | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) to Post Q1 2025 Earnings of $2.39 Per Share, Zacks Research ForecastsBio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Investment analysts at Zacks Research upped their Q1 2025 earnings estimates for Bio-Rad Laboratories in a research report issued to clients and investors on Monday, April 15th. Zacks Research analyst R. Anand now forecasts that the medical reApril 16, 2024 | marketbeat.comZacks Research Equities Analysts Reduce Earnings Estimates for Bio-Rad Laboratories, Inc. (NYSE:BIO)Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Equities researchers at Zacks Research cut their Q1 2024 EPS estimates for Bio-Rad Laboratories in a research note issued to investors on Monday, April 15th. Zacks Research analyst R. Anand now anticipates that the medical research company wilApril 13, 2024 | marketbeat.comLecap Asset Management Ltd. Purchases New Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)Lecap Asset Management Ltd. acquired a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 4,925 shares of the medical research company's stock, valued at approximately $1,590,0April 12, 2024 | marketbeat.comRaymond James & Associates Sells 21,649 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)Raymond James & Associates cut its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 62.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,083 shares of the medical research company's stoApril 11, 2024 | marketwatch.comOncocyte, Bio-Rad Partner on Global Launch of Transplant AssayApril 11, 2024 | seekingalpha.comOncocyte stock rallies 90% post-market on Bio-Rad partnershipApril 11, 2024 | marketbeat.comBio-Rad Laboratories (NYSE:BIO) Stock Price Down 3.9%Bio-Rad Laboratories (NYSE:BIO) Trading Down 3.9%April 11, 2024 | marketbeat.comAllspring Global Investments Holdings LLC Has $53.64 Million Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)Allspring Global Investments Holdings LLC increased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 11.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 166,127 shares ofApril 10, 2024 | businesswire.comBio-Rad's Chief Operating Officer Andrew Last to RetireApril 5, 2024 | marketbeat.comBio-Rad Laboratories (NYSE:BIO) Downgraded by StockNews.com to "Hold"StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Friday.April 4, 2024 | marketbeat.comQ2 2024 Earnings Forecast for Bio-Rad Laboratories, Inc. Issued By Zacks Research (NYSE:BIO)Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Investment analysts at Zacks Research reduced their Q2 2024 earnings per share (EPS) estimates for shares of Bio-Rad Laboratories in a note issued to investors on Tuesday, April 2nd. Zacks Research analyst R. Anand now expects that the medicalApril 3, 2024 | finance.yahoo.comGlobal Clinical Microbiology Market Size To Worth USD 6.58 Billion By 2033 | CAGR of 4.49%April 3, 2024 | marketbeat.comBio-Rad Laboratories (NYSE:BIO) Shares Gap Down to $328.72Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down to $328.72April 3, 2024 | msn.comStocks Waver on Higher Bond Yields Ahead of Fed Chair PowellApril 3, 2024 | marketbeat.comCitigroup Lowers Bio-Rad Laboratories (NYSE:BIO) to NeutralCitigroup cut Bio-Rad Laboratories from a "buy" rating to a "neutral" rating and dropped their price target for the company from $400.00 to $365.00 in a report on Wednesday.April 3, 2024 | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) Given Consensus Rating of "Buy" by AnalystsBio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) has been assigned a consensus rating of "Buy" from the four research firms that are currently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy recommendation. The average 12 month targApril 3, 2024 | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) to Post Q1 2024 Earnings of $2.09 Per Share, Zacks Research ForecastsBio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Research analysts at Zacks Research cut their Q1 2024 earnings estimates for shares of Bio-Rad Laboratories in a note issued to investors on Tuesday, April 2nd. Zacks Research analyst R. Anand now expects that the medical research company willApril 3, 2024 | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Fifth Third BancorpFifth Third Bancorp trimmed its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 28.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 9,509 shares of the medical research company's stock after selling 3,793April 2, 2024 | marketbeat.comBio-Rad Laboratories, Inc. (NYSE:BIO) Short Interest Up 15.1% in MarchBio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 579,300 shares, a growth of 15.1% from the February 29th total of 503,400 shares. Based on an average daily volume of 197,700 shares, the days-to-cover ratio is currently 2.9 days. Approximately 2.9% of the shares of the company are sold short.April 2, 2024 | marketbeat.comAssenagon Asset Management S.A. Has $4.07 Million Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)Assenagon Asset Management S.A. grew its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 104.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,605 shares of the medical research company's stock a Get Bio-Rad Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter. Email Address The most important AI company you've never heard of (Ad)Because this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products. Get the full story on this secret AI company poised for massive growth BIO Media Mentions By Week BIO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIO News Sentiment▼0.360.55▲Average Medical News Sentiment BIO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIO Articles This Week▼105▲BIO Articles Average Week Get Bio-Rad Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Illumina News Waters News Bio-Rad Laboratories News Revvity News 10x Genomics News Olink Holding AB (publ) News Avantor News Ascendis Pharma A/S News Penumbra News Cerevel Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:BIO) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHow to Play the AI and Crypto Markets in One SwingWeiss RatingsAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Rad Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
